CA3245985A1 - FORMULATIONS CONTAINING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN - Google Patents
FORMULATIONS CONTAINING MELPHALAN FLUFENAMIDE AND CYCLODEXTRINInfo
- Publication number
- CA3245985A1 CA3245985A1 CA3245985A CA3245985A CA3245985A1 CA 3245985 A1 CA3245985 A1 CA 3245985A1 CA 3245985 A CA3245985 A CA 3245985A CA 3245985 A CA3245985 A CA 3245985A CA 3245985 A1 CA3245985 A1 CA 3245985A1
- Authority
- CA
- Canada
- Prior art keywords
- melphalan flufenamide
- pharmaceutical preparation
- ycd
- cyclodextrin
- hpycd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204171.9A GB202204171D0 (en) | 2022-03-24 | 2022-03-24 | Novel formulations |
| GB2204171.9 | 2022-03-24 | ||
| PCT/EP2023/057729 WO2023180565A1 (en) | 2022-03-24 | 2023-03-24 | Formulations comprising melphalan flufenamide and cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245985A1 true CA3245985A1 (en) | 2023-09-28 |
Family
ID=81449463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245985A Pending CA3245985A1 (en) | 2022-03-24 | 2023-03-24 | FORMULATIONS CONTAINING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250205155A1 (https=) |
| EP (1) | EP4499049A1 (https=) |
| JP (1) | JP2025510725A (https=) |
| KR (1) | KR20240161664A (https=) |
| CN (1) | CN119053323A (https=) |
| AU (1) | AU2023241241A1 (https=) |
| CA (1) | CA3245985A1 (https=) |
| GB (1) | GB202204171D0 (https=) |
| IL (1) | IL315551A (https=) |
| MX (1) | MX2024011654A (https=) |
| WO (1) | WO2023180565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025233915A1 (en) * | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| DK2701720T3 (en) | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
-
2022
- 2022-03-24 GB GBGB2204171.9A patent/GB202204171D0/en not_active Ceased
-
2023
- 2023-03-24 WO PCT/EP2023/057729 patent/WO2023180565A1/en not_active Ceased
- 2023-03-24 JP JP2024556113A patent/JP2025510725A/ja active Pending
- 2023-03-24 IL IL315551A patent/IL315551A/en unknown
- 2023-03-24 CN CN202380035203.1A patent/CN119053323A/zh active Pending
- 2023-03-24 CA CA3245985A patent/CA3245985A1/en active Pending
- 2023-03-24 US US18/849,977 patent/US20250205155A1/en active Pending
- 2023-03-24 EP EP23720032.4A patent/EP4499049A1/en active Pending
- 2023-03-24 KR KR1020247034012A patent/KR20240161664A/ko active Pending
- 2023-03-24 AU AU2023241241A patent/AU2023241241A1/en active Pending
-
2024
- 2024-09-23 MX MX2024011654A patent/MX2024011654A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023241241A1 (en) | 2024-10-31 |
| WO2023180565A1 (en) | 2023-09-28 |
| EP4499049A1 (en) | 2025-02-05 |
| US20250205155A1 (en) | 2025-06-26 |
| CN119053323A (zh) | 2024-11-29 |
| JP2025510725A (ja) | 2025-04-15 |
| KR20240161664A (ko) | 2024-11-12 |
| MX2024011654A (es) | 2025-01-09 |
| GB202204171D0 (en) | 2022-05-11 |
| IL315551A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100941210B1 (ko) | 백금 유도체를 포함하는 제약 제제 | |
| JP6516831B2 (ja) | シクロホスファミド液状濃縮物の製剤 | |
| JP6106228B2 (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液 | |
| JP2016117748A (ja) | シクロデキストリン誘導体を含む注射用メルファラン組成物並びにその製造及び使用方法 | |
| RU2566262C2 (ru) | Стабилизированная композиция вориконазола | |
| US20220047509A1 (en) | Stabilized liquid formulation of levothyroxine | |
| CN107206014A (zh) | 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法 | |
| JP2016521731A (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| WO2018138557A1 (en) | Ready-to-use carfilzomib compositions | |
| US20250205155A1 (en) | Formulations comprising melphalan flufenamide and cyclodextrin | |
| KR20200052326A (ko) | 코판리십의 제제 | |
| CN108601730A (zh) | 万古霉素的制剂 | |
| EP3873529A1 (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| EP4055005A1 (en) | Liquid melphalan composition | |
| WO2013032184A2 (ko) | 피라지노-트리아진 유도체를 포함하는 조성물 | |
| EA052092B1 (ru) | Препараты, содержащие мелфалана флуфенамид и циклодекстрин | |
| TW202412832A (zh) | 催產素配方 | |
| CN111107837A (zh) | 包含西普尼莫德的肠胃外制剂 | |
| CZ300120B6 (cs) | Farmaceutická kompozice pro injekcní podání | |
| CN120529922A (zh) | 肽药物偶联物 | |
| HK1233162A1 (en) | Formulations of cyclophosphamide liquid concentrate | |
| HK1259054A1 (zh) | 万古霉素的制剂 | |
| EA023081B1 (ru) | Инъекционная лекарственная форма флупиртина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240913 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240916 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240916 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241216 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |